SAB Biotherapeutics Inc (SABS) is an American biopharmaceutical company at the forefront of groundbreaking advancements in the field of immunotherapy. Founded by Eddie J. Sullivan, PhD, the firm harnesses the science of genomics to create new methodologies for battling severe diseases.
Situated in Sioux Falls, South Dakota, SAB Biotherapeutics focuses on developing human antibodies with the use of advanced genetics and immunology. Their approach, based on the company's remarkable platform technology, produces fully human polyclonal antibodies without relying on human donors. This innovative method makes the company's drug production socially responsible, sustainable and capable of meeting global demand.
At the heart of SAB Biotherapeutics' innovative strategy is the transchromosomic cattle (Tc Bovine™) technology. This revolutionary scientific breakthrough genetically engineers cattle to carry a small section of human chromosome which enables them to produce 100% human antibodies. When the cattle are immunized with an antigen - a substance prompting an immune response, they start producing large amounts of human polyclonal antibodies. The antibodies are then isolated to create disease-specific immunotherapies.
Perhaps the ground-breaking nature of SAB Biotherapeutics' work is most evident in how it responded to global health crises. Their platform has the capability to react to emerging health threats efficiently, providing rapid and scalable development of new therapeutics. This was demonstrated during the Ebola and Zika virus outbreaks, where SAB Biotherapeutics managed to develop specific antibody therapeutics within weeks of receiving the genetic sequence of the virus.
More recently, their novel approach was used in response to the global COVID-19 pandemic. Without requiring COVID-19 patient plasma, SAB Biotherapeutics was able to create SAB-185, a treatment candidate with a high potency against SARS-CoV-2. The company believes it has the potential to redefine the way we combat the virus.
Innovative and motivated, SAB Biotherapeutics continues to make significant strides in the biopharmaceutical industry with its unique and powerful approach. Through commitment to scientific excellence and dedication to resolving the global health crises, SAB Biotherapeutics distinguishes itself as a leader in producing human polyclonal antibodies, accomplishing an important responsibility towards the advancement of human health.